Sanofi's SERD Candidate Founders In Advanced Breast Cancer
But Hope Remains For Earlier Setting
The French major’s amcenestrant has missed its primary endpoint in a Phase II study of advanced breast cancer patients but could still have potential in earlier adjuvant disease.
You may also be interested in...
The major’s atopic dermatitis blockbuster made more than €1.6bn this quarter, but the firm’s R&D costs are rising as it attempts to add some fresh blood to its stagnating pipeline.
Roche's giredestrant failed to show a benefit on progression-free survival in the Phase II acelERA trial in people with advanced breast cancer.
Looking to catch up with leaders in in the field of next-generation antibodies, Sanofi has struck a deal with IGM Biosciences for three cancer and three auto-immune/inflammation IgM candidates that hold the promise of greater efficacy.